CTOs on the Move

Natrol subsidiary of Plethico Pharmaceuticals Li

www.natrol.com

 
Natrol, Inc. subsidiary of Plethico Pharmaceuticals Limited is a Chatsworth, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.natrol.com
  • 21411 Prairie St
    Chatsworth, CA USA 91311
  • Phone: 818.739.6000

Executives

Name Title Contact Details

Similar Companies

Dr. Thompson's Inc

Dr. Thompson's Inc is a Westerville, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NascoHealthcare

Nasco Healthcare simulation for healthcare training solutions ensures frontline heroes are READY in any situation. 5-year warranty and 100% made in the US.

Purdue Pharma L.P.

Purdue Pharma LP is a privately held pharmaceutical company founded by John Purdue Gray.

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Revive Therapeutics

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.